survodutide vs Zabopegdutide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in Obesitypeptide
Partial signal

NCT06077864 · Phase 3 · completed

The study randomly assigns 5,531 participants to two survodutide doses or placebo and uses quadruple blinding. Its primary endpoint is a hard clinical composite of cardiovascular death, nonfatal stroke, nonfatal heart attack, coronary revascularization, or heart-failure events, but the non-inferiority result is not yet available.

Next expected readout: December 2026 · NCT07768813 (registry estimate)

Reported efficacy

Percentage change in body weight from baseline to Week 76 (Baseline and at Week 76); Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76 (Baseline and at Week 76): Percentage change in body weight from baseline to Week 76 (SYNCHRONIZE-1, primary analysis, treatment-regimen estimand): -13.0% survodutide 6.0 mg and -12.2% 3.6 mg vs -5.4% placebo; body weight reduction of at least 5%: 71.9% and 72.6% vs 46.3% (P<0.001 for all comparisons with placebo). (met)

Result source: NCT06066515

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in Obesitypeptide
Partial signal

NCT04812262 · Phase 1 · completed

This Phase 1 study randomized overweight or obese adults with type 2 diabetes and fatty liver disease to DD01 or placebo in sequential single and multiple ascending-dose cohorts, with quadruple blinding and 255 participants in total. All of its registered primary endpoints measured safety and tolerability, so the trial made no formal efficacy test, and no results were posted on the registry. The sponsor announced a reduction in liver fat measured by MRI-PDFF in the high-dose group (p < 0.0001 versus placebo), but that outcome was not a registered primary endpoint and the figure comes from a company press release.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Number of participants with treatment-related adverse events and serious adverse events (Part A - 43 days); Number of participants with treatment-related adverse events and serious adverse events (TEAEs) (Part B - 57 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part A - 43 days); Number of participants with clinically significant abnormalities in clinical laboratory values (Part B - 57 days); Number of participants with clinically significant abnormalities in physical examinations (Part A - 43 days); Number of participants with clinically significant abnormalities in physical examinations (Part B - 57 days); Number of participants with clinically significant abnormalities in vital signs (Part A - 43 days); Number of participants with clinically significant abnormalities in vital signs (Part B - 57 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part A - 43 days); Blood Pressure assessed by 24-hour ambulatory blood pressure monitoring (ABPM) (Part B - 57 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part A - 43 days); Heart Rate assessed by 24-hour ambulatory electrocardiography monitoring reader) (Part B - 57 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part A - 43 days); Number of participants with clinically significant abnormalities in 12-lead ECGs (Part B - 57 days): Randomized, double-blind, placebo-controlled single and multiple ascending dose study at four US clinical sites: following only 4 weeks of treatment, all subjects in the high dose group achieved at least a 40% reduction in liver fat, with a mean reduction of more than 50% measured by MRI-PDFF (p < 0.0001 versus placebo). (not_applicable)

Result source: NCT04812262

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointsurvodutideZabopegdutide
Body weight, % change-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515
—Not reported
Weight loss of 5% or more82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
—Not reported
Weight loss of 10% or more68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
—Not reported
Waist circumference, change (cm)-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
—Not reported

Body weight, % change

survodutide
-14.9% vs -2.8%−12.1 vs placebo4.8 mg · wk 46 · n 76NCT04667377
4 other results
  • -13.2% vs -2.8% 3.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -12.5% vs -2.8% 2.4 mg · wk 46 · n 78 · Phase 2 · primary NCT04667377
  • -6.2% vs -2.8% 0.6 mg · wk 46 · n 76 · Phase 2 · primary NCT04667377
  • -16.6% vs -3.2% wk 76 · Phase 3 · primary NCT06066515
Zabopegdutide
—Not reported

Weight loss of 5% or more

survodutide
82.8% vs 25.9%+56.9 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 82% vs 25.9% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 81% vs 25.9% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 60.7% vs 25.9% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Zabopegdutide
—Not reported

Weight loss of 10% or more

survodutide
68.8% vs 11.1%+57.7 vs placebo4.8 mg · wk 46 · n 64NCT04667377
3 other results
  • 65.6% vs 11.1% 3.6 mg · wk 46 · n 61 · Phase 2 · secondary NCT04667377
  • 65.5% vs 11.1% 2.4 mg · wk 46 · n 58 · Phase 2 · secondary NCT04667377
  • 33.9% vs 11.1% 0.6 mg · wk 46 · n 56 · Phase 2 · secondary NCT04667377
Zabopegdutide
—Not reported

Waist circumference, change (cm)

survodutide
-16.0 vs -4.0−12 vs placebo4.8 mg · wk 46 · n 75NCT04667377
3 other results
  • -15.0 vs -4.0 3.6 mg · wk 46 · n 74 · Phase 2 · secondary NCT04667377
  • -15.0 vs -4.0 2.4 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
  • -8.3 vs -4.0 0.6 mg · wk 46 · n 71 · Phase 2 · secondary NCT04667377
Zabopegdutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zabopegdutide: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. survodutide: 4 of 4 rows · Zabopegdutide: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsurvodutide
Dropout rate
—4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
28.6%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.4%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
23.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
29.5%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
23.4%4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
18.2%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
14.1%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
16.7%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Serious AEs
7.4%4.8 mga
NCT04667377 · Phase 2 · registry result, not featured evidence
show 7 more results
—4.8 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
5.6%3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
3.3%2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
2.2%0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
—0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
4.8 mga
nausea 59.3% (placebo 19.5%)
constipation 24.1% (placebo 5.2%)
vomiting 24.1% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
3.6 mg
nausea 63.4% (placebo 19.5%)
vomiting 39.4% (placebo 5.2%)
constipation 31% (placebo 5.2%)
NCT04667377 · Phase 2 · registry result, not featured evidence
2.4 mg
nausea 65.2% (placebo 19.5%)
vomiting 30.4% (placebo 5.2%)
diarrhoea 22.8% (placebo 10.4%)
NCT04667377 · Phase 2 · registry result, not featured evidence
0.6 mg
nausea 39.1% (placebo 19.5%)
diarrhoea 23.9% (placebo 10.4%)
covid-19 19.6% (placebo 22.1%)
NCT04667377 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

survodutide

Weight -14.94% (n=76) vs -2.82% (n=77) placebo @ 46wk4.8 mg
percent change · % of baseline
NCT04667377 · Phase 2 · registry result, not featured evidence
show 4 more results
-13.22% (n=76) vs -2.82% (n=77) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-12.51% (n=78) vs -2.82% (n=77) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-6.19% (n=76) vs -2.82% (n=77) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-16.6% vs -3.2% placebo @ 76wk
NCT06066515 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 82.8% (n=64) vs 25.9% (n=54) placebo @ 46wk4.8 mg
responder rate · % of participants
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
82% (n=61) vs 25.9% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
81% (n=58) vs 25.9% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
60.7% (n=56) vs 25.9% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight Loss 10% 68.8% (n=64) vs 11.1% (n=54) placebo @ 46wk4.8 mg
responder rate · % of participants
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
65.6% (n=61) vs 11.1% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
65.5% (n=58) vs 11.1% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
33.9% (n=56) vs 11.1% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight Loss 15% 54.7% (n=64) vs 5.6% (n=54) placebo @ 46wk4.8 mg
absolute value · percentage points
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
45.9% (n=61) vs 5.6% (n=54) placebo @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
37.9% (n=58) vs 5.6% (n=54) placebo @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
12.5% (n=56) vs 5.6% (n=54) placebo @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Weight -18.47 vs -2.68 placebo kg @ 46wk4.8 mg
absolute change · kg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-15.64 vs -2.68 placebo kg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.75 vs -2.68 placebo kg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-7.21 vs -2.68 placebo kg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
Waist Circumference Change -16.01 vs -3.96 placebo cm @ 46wk4.8 mg
absolute change · cm
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-14.96 vs -3.96 placebo cm @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-14.99 vs -3.96 placebo cm @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.32 vs -3.96 placebo cm @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
SBP -8.62 vs -2.46 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-8.66 vs -2.46 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-8.08 vs -2.46 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-6.19 vs -2.46 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
DBP -4.8 vs -1.87 placebo mmHg @ 46wk4.8 mg
absolute change · mmHg
NCT04667377 · Phase 2 · registry result, not featured evidence
show 3 more results
-4.31 vs -1.87 placebo mmHg @ 46wk3.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-4.36 vs -1.87 placebo mmHg @ 46wk2.4 mg
NCT04667377 · Phase 2 · registry result, not featured evidence
-3.31 vs -1.87 placebo mmHg @ 46wk0.6 mg
NCT04667377 · Phase 2 · registry result, not featured evidence

MASH / NASH

Shared mechanism: GLP-1/glucagon receptor (dual) · full MASH / NASH pipeline

survodutide

Developed by Boehringer Ingelheim under a licence from Zealand Pharma

Phase 3 in MASH / NASHpeptide
Reliable signal

NCT06309992 · Phase 3 · completed

This phase 3 trial randomly assigned 216 adults with obesity and at-risk MASLD (2:1) to weekly survodutide 6.0 mg or placebo, with double-blind treatment for 48 weeks. The first co-primary endpoint was a reduction of at least 30% in liver fat on MRI: 84.2% of survodutide patients reached it against 24.3% on placebo (P<0.0001). The second co-primary endpoint was body weight change: -12.2% against -1.0% (P<0.0001). Both co-primary endpoints were met, so the result is met. The figures come from the peer-reviewed Nature Medicine paper.

Next expected readout: April 2029 · NCT07850063 (registry estimate)

Reported efficacy

Relative reduction in liver fat content of at least 30% from baseline to Week 48 (yes/no) assessed by magnetic resonance imaging proton density fat fraction (MRI-PDFF) [%] (at baseline, at week 48); Relative change (%) in body weight [kg] from baseline to Week 48 (at baseline, at week 48): Co-primary 1, ≥30% reduction in MRI-PDFF liver fat content at week 48: 84.2% survodutide 6.0 mg vs 24.3% placebo (efficacy estimand, P<0.0001; treatment regimen estimand 68.5% vs 28.6%, P<0.0001), met. Co-primary 2, percentage change in body weight at week 48: -12.2% vs -1.0% (efficacy estimand, P<0.0001; treatment regimen estimand -8.7% vs -1.4%, P<0.0001), met. (met)

Result source: NCT06309992

Zabopegdutide

Developed by D&D Pharmatech and partners

Phase 2 in MASH / NASHpeptide
Partial signal

NCT06410924 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial enrolled 67 people with fatty liver disease and measured the proportion who achieved at least a 30% reduction in liver fat, measured by MRI scan, after 12 weeks. DD01 met this imaging-based endpoint far more often than placebo (75.8% vs 11.8%), though liver-fat reduction on imaging is an earlier marker of benefit rather than the biopsy-confirmed liver-disease improvement that later-stage trials assess.

Reported efficacy

Proportion of subjects who achieve at least 30% liver fat reduction measured by MRI-PDFF (12 weeks): Proportion of subjects achieving at least 30% liver fat reduction by MRI-PDFF at 12 weeks: 75.8% (DD01) vs 11.8% (placebo); p<0.0001. (met)

Result source: NCT06410924

Results for MASH / NASH

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointsurvodutideZabopegdutide
MASH resolution without fibrosis worsening—Not posted · NCT06309992—Not reported
Fibrosis stage, change—Not posted · NCT06309992—Not reported
Liver fat (MRI-PDFF), change-13.0% vs -1.9%−11.1 vs placebo6.0 mg · wk 48 · n 51NCT04771273
11 other results
  • -12.5% vs -1.6% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -64.3% vs -7.3% 6.0 mg · wk 48 · n 51 · Phase 2 · secondary NCT04771273
  • -62.0% vs -5.7% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -12.8% vs -1.9% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -12.4% vs -1.6% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -62.8% vs -7.3% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -60.8% vs -5.7% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -10.5% vs -1.9% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -10.7% vs -1.6% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
  • -50.9% vs -7.3% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -52.2% vs -5.7% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
—Not reported
ALT, change—Not posted · NCT06309992—Not reported

MASH resolution without fibrosis worsening

survodutide
—Not posted · NCT06309992
Zabopegdutide
—Not reported

Fibrosis stage, change

survodutide
—Not posted · NCT06309992
Zabopegdutide
—Not reported

Liver fat (MRI-PDFF), change

survodutide
-13.0% vs -1.9%−11.1 vs placebo6.0 mg · wk 48 · n 51NCT04771273
11 other results
  • -12.5% vs -1.6% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -64.3% vs -7.3% 6.0 mg · wk 48 · n 51 · Phase 2 · secondary NCT04771273
  • -62.0% vs -5.7% 6.0 mg · wk 48 · n 58 · Phase 2 · secondary NCT04771273
  • -12.8% vs -1.9% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -12.4% vs -1.6% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -62.8% vs -7.3% 4.8 mg · wk 48 · n 60 · Phase 2 · secondary NCT04771273
  • -60.8% vs -5.7% 4.8 mg · wk 48 · n 64 · Phase 2 · secondary NCT04771273
  • -10.5% vs -1.9% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -10.7% vs -1.6% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
  • -50.9% vs -7.3% 2.4 mg · wk 48 · n 68 · Phase 2 · secondary NCT04771273
  • -52.2% vs -5.7% 2.4 mg · wk 48 · n 61 · Phase 2 · secondary NCT04771273
Zabopegdutide
—Not reported

ALT, change

survodutide
—Not posted · NCT06309992
Zabopegdutide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. survodutide: 5 of 5 rows · Zabopegdutide: 1 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsurvodutideZabopegdutide
MRI-PDFF ≥30%
responder rate · % of participants
76.9% (n=52) vs 16.5% (n=79) placebo @ 48wk6.0 mga,b,c,d
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more doses
56.8% (n=74) vs 13.5% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
66.7% (n=69) vs 16.5% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
66.7% (n=72) vs 13.5% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
50.5% (n=93) vs 16.5% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
63% (n=73) vs 13.5% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
75.8% vs 11.8% placebo @ 12wkb,c,d
NCT06410924 · Phase 2 · sponsor-reported, not registry data
Dropout rate
—6.0 mge
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
24%6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
13.7%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
15.1%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—
Discontinued due to AEs
—6.0 mge
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
16%6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
12.3%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
11%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—
Serious AEs
9.6%6.0 mge
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
—6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
10.1%4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
5.4%2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
—
Most frequent reported AEs
6.0 mge
nausea 63.5% (placebo 27.8%)
diarrhoea 55.8% (placebo 25.3%)
constipation 28.8% (placebo 17.7%)
NCT04771273 · Phase 2 · registry result, not featured evidence
show 2 more results
4.8 mg
nausea 66.7% (placebo 27.8%)
diarrhoea 53.6% (placebo 25.3%)
vomiting 47.8% (placebo 7.6%)
NCT04771273 · Phase 2 · registry result, not featured evidence
2.4 mg
nausea 64.5% (placebo 27.8%)
diarrhoea 40.9% (placebo 25.3%)
vomiting 40.9% (placebo 7.6%)
NCT04771273 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: registered conditions differ.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 48 weeks versus 12 weeks.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

survodutide

Histologic Improvement 55.8% (n=52) vs 15.2% (n=79) placebo @ 48wk6.0 mg
responder rate · % of participants
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
43.2% (n=74) vs 13.5% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
63.8% (n=69) vs 15.2% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
62.5% (n=72) vs 13.5% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
38.7% (n=93) vs 15.2% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
46.6% (n=73) vs 13.5% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Liver Fat -12.96% (n=51) vs -1.89% (n=73) placebo @ 48wk6.0 mg
absolute change · percentage points
NCT04771273 · Phase 2 · registry result, not featured evidence
show 11 more results
-12.48% (n=58) vs -1.61% (n=69) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-64.3% (n=51) vs -7.28% (n=73) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-61.97% (n=58) vs -5.71% (n=69) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-12.8% (n=60) vs -1.89% (n=73) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-12.4% (n=64) vs -1.61% (n=69) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-62.79% (n=60) vs -7.28% (n=73) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-60.82% (n=64) vs -5.71% (n=69) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-10.48% (n=68) vs -1.89% (n=73) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-10.73% (n=61) vs -1.61% (n=69) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-50.92% (n=68) vs -7.28% (n=73) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-52.2% (n=61) vs -5.71% (n=69) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
Fibrosis Improvement 1-Stage Without NASH Worsening 44.2% (n=52) vs 21.5% (n=79) placebo @ 48wk6.0 mg
responder rate · % of participants
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
33.8% (n=74) vs 21.6% (n=74) placebo @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
34.8% (n=69) vs 21.5% (n=79) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
36.1% (n=72) vs 21.6% (n=74) placebo @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
30.1% (n=93) vs 21.5% (n=79) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
34.2% (n=73) vs 21.6% (n=74) placebo @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
NAS -3.3 vs -0.4 placebo score @ 48wk6.0 mg
absolute change · score
NCT04771273 · Phase 2 · registry result, not featured evidence
show 5 more results
-3.3 vs -0.2 placebo score @ 48wk6.0 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-3.2 vs -0.4 placebo score @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-3.2 vs -0.2 placebo score @ 48wk4.8 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-2.8 vs -0.4 placebo score @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence
-2.8 vs -0.2 placebo score @ 48wk2.4 mg
NCT04771273 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: survodutide's landscape · Zabopegdutide's landscape